Use: Labeled indications
- PROSCAR, is a 5α-reductase inhibitor, indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate t
- Improve symptoms Reduce the risk of acute urinary retention Reduce the risk of the need for surgery including transurethral resection of the prostate (TURP) and prostatectomy.
Full indications and usage US FDA label
1 INDICATIONS AND USAGE PROSCAR, is a 5α-reductase inhibitor, indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate to (1.1): Improve symptoms Reduce the risk of acute urinary retention Reduce the risk of the need for surgery including transurethral resection of the prostate (TURP) and prostatectomy. PROSCAR administered in combination with the alpha-blocker doxazosin is indicated to reduce the risk of symptomatic progression of BPH (a confirmed ≥4 point increase in American Urological Association (AUA) symptom score) (1.2).
Limitations of Use: PROSCAR is not approved for the prevention of prostate cancer (1.3). 1.1 Monotherapy PROSCAR ® is indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate to: - Improve symptoms - Reduce the risk of acute urinary retention - Reduce the risk of the need for surgery including transurethral resection of the prostate (TURP) and prostatectomy. 1.2 Combination with Alpha-Blocker PROSCAR administered in combination with the alpha-blocker doxazosin is indicated to reduce the risk of symptomatic progression of BPH (a confirmed ≥4 point increase in American Urological Association (AUA) symptom score). 1.3 Limitations of Use PROSCAR is not approved for the prevention of prostate cancer.
Contraindications
4 CONTRAINDICATIONS PROSCAR is contraindicated in the following: Hypersensitivity to any component of this medication. Pregnancy. Finasteride use is contraindicated in females when they are or may potentially be pregnant. Because of the ability of Type II 5α-reductase inhibitors to inhibit the conversion of testosterone to 5α-dihydrotestosterone (DHT), finasteride may cause abnormalities of the external genitalia of a male fetus of a pregnant female who receives finasteride.
If this drug is used during pregnancy, or if pregnancy occurs while taking this drug, the pregnant female should be apprised of the potential hazard to the male fetus. [See also Warnings and Precautions (5.3), Use in Specific Populations (8.1), and How Supplied/Storage and Handling (16).] In female rats, low doses of finasteride administered during pregnancy have produced abnormalities of the external genitalia in male offspring. Hypersensitivity to any components of this product (4).
Females who are or may potentially be pregnant (4, 5.3, 8.1, 16).
US FDA labelDosing: Adult
PROSCAR may be administered with or without meals. PROSCAR may be administered with or without meals (2). Monotherapy: One tablet (5 mg) taken once a day (2.1). Combination with Doxazosin: One tablet (5 mg) taken once a day in combination with the alpha-blocker doxazosin (2.2).
2.1 Monotherapy
2.1 Monotherapy The recommended dose of PROSCAR is one tablet (5 mg) taken once a day [see Clinical Studies (14.1)].
2.2 Combination with Alpha-Blocker
2.2 Combination with Alpha-Blocker The recommended dose of PROSCAR is one tablet (5 mg) taken once a day in combination with the alpha-blocker doxazosin [see Clinical Studies (14.2)].
Dosing: Altered kidney function
8.7 Renal Impairment No dosage adjustment is necessary in patients with renal impairment [see Clinical Pharmacology (12.3)].
Renal Impairment No dosage adjustment is necessary in patients with renal impairment. In patients with chronic renal impairment, with creatinine clearances ranging from 9.0 to 55 mL/min, AUC, maximum plasma concentration, half-life, and protein binding after a single dose of 14 C-finasteride were similar to values obtained in healthy volunteers.
Urinary excretion of metabolites was decreased in patients with renal impairment. This decrease was associated with an increase in fecal excretion of metabolites. Plasma concentrations of metabolites were significantly higher in patients with renal impairment (based on a 60% increase in total radioactivity AUC). However, finasteride has been well tolerated in BPH patients with normal renal function receiving up to 80 mg/day for 12 weeks, where exposure of these patients to metabolites would presumably be much greater.
Kidney-specific guidance from renalcarematters.com: in preparation.
Dosing: Hepatic impairment
8.6 Hepatic Impairment Caution should be exercised in the administration of PROSCAR in those patients with liver function abnormalities, as finasteride is metabolized extensively in the liver [see Clinical Pharmacology (12.3)].
US FDA labelDosing: Pediatric
Pediatric use (US label) US FDA label
8.4 Pediatric Use PROSCAR is not indicated for use in pediatric patients. Safety and effectiveness in pediatric patients have not been established.
Dosing: Older adult
Geriatric use (US label) US FDA label
8.5 Geriatric Use Of the total number of subjects included in PLESS, 1480 and 105 subjects were 65 and over and 75 and over, respectively. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients. No dosage adjustment is necessary in the elderly [see Clinical Pharmacology (12.3) and Clinical Studies (14)].
Dosage forms
Philippines
- Film-coated tablet: 1 mg, 5 mg
- Tablet: 1 mg, 5 mg
Registered products in the Philippines
50 products registered with the Food and Drug Administration (FDA) Philippines list Finasteride as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.
All registered products50
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
AteprosFinasteride | 5 mg Film-Coated TabletStrip Foil x 10's Box of 30's | Rx | Amherst Laboratories, Inc.Philippines | Trader: BIOMEDIS, INC. | DRP-9782 | Aug 5, 2029 | |
DimaFinasteride | 1 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Sydler Remedies Pvt. LimitedIndia | Pharmasia-Cuvest IncorporatedImporter: Ambica International CorporationTrader: Natracare Inc. | DRP-5349-01 | Jun 18, 2029 | |
FenastiphilFinasteride | 5 mg TabletAlu/Clear PVC Blister Pack x 10’s (Box of 30’s) | Rx | Globela Pharma Private LimitedIndia | Philrx Pharma Inc.Importer: Amb Hk Enterprises Inc. | DRP-16110-01 | Oct 30, 2029 | |
FenchrideFinasteride | 5 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 3 blister packs x 10 tablets) | Rx | Stallion Laboratories Pvt. Ltd.India | Ambica International Corporation | DRP-13702 | Mar 29, 2028 | |
Figna-5Finasteride | 5 mg Film-Coated TabletAlu/PVC Blister Pack x 14's (Box of 28's) | Rx | Gnana Life Sciences Pvt. Ltd.India | Curasave PharmaImporter: Ambica International Corporation | DRP-5946 | Jan 21, 2030 | |
Fina-5Finasteride | 5 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 100’s) | Rx | Cooper Pharma LimitedIndia | Medchoice Pharma, Inc.Importer: Ambica International Corporation | DRP-5755 | Nov 7, 2029 | |
Finaget-5Finasteride | 5 mg Film-Coated TabletAlu-Alu Blister Pack x 10's (Box of 100's) | Rx | West Coast Pharmaceutical Works Ltd.India | 2MG Incorporated | DRP-17811 | Mar 12, 2031 | |
Finaplasia-1Finasteride | 1 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Sydler Remedies Pvt. LimitedIndia | Ambica International Corporation | DRP-5349 | Jun 18, 2029 | |
Finaplasia-5Finasteride | 5 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30’s) | Rx | Sydler Remedies Pvt. Ltd.India | Ambica International Corporation | DRP-4703 | Sep 9, 2028 | |
FinaprosFinasteride | 5 mg Film-Coated TabletAlu/PVC Blister Pack x 10 's (Box of 100's) | Rx | UNICURE REMEDIES PVT. LTD.India | NEXT CHEMICAL ENTERPRISES | DRP-4731 | Apr 8, 2028 | |
FinarFinasteride | 5 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 30's) | Rx | Unicure Remedies Pvt. Ltd.India | Ambicare Pharmaceuticals Inc.Importer: Ambica International Corporation | DRP-4725-01 | Sep 20, 2028 | |
FinaridFinasteride | 5 mg Film-Coated TabletAlu/ PVC Blister Pack x 10's (Box of 30's) | Rx | Unicure Remedies Pvt. LtdIndia | ECE Pharmaceuticals, Inc.Importer: AAA Pharma, Inc. | DRP-6154 | Jan 18, 2028 | |
FinasiaFinasteride | 5 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 30's) | Rx | Unicure Remedies Pvt. Ltd.India | Ambica International Corporation | DRP-4725 | Sep 20, 2028 | |
FinastedinFinasteride | 5 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 30's) | Rx | Stallion Laboratories Pvt. Ltd.India | Medchoice Urology Nephro Pharma Inc.Importer: Ambica International Corporation | DRP-4265-02 | Feb 26, 2028 | |
FinasticareFinasteride | 5 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30’s) | Rx | Sydler Remedies Pvt. Ltd.India | Medcare PharmaceuticalsImporter: Ambica International Corporation | DRP-4703-01 | Sep 9, 2028 | |
Finflow-5Finasteride | 5 mg Film-Coated TabletAlu/PVC Blister Pack x 10’s (Box of 100’s) | Rx | West Coast Pharmaceutical Works Ltd.India | Macropharma CorporationImporter: Ambica International CorporationTrader: Swati Spentose Pvt. Ltd. | DRP-4827 | Oct 16, 2029 | |
FiniodFinasteride | 5mg Film - Coated tablet | Rx | JW PHARMACEUTICAL CORPORATION | MEDLINK MARKETING | DR-XY45664 | Nov 22, 2026 | |
FinnfinazFinasteride | 5 mg Film-Coated TabletAlu/PVC Blister Pack x 10’s (Box of 100’s) | Rx | West Coast Pharmaceutical Works Ltd.India | Diafarm Inc.Importer: Ambica International CorporationTrader: Swati Spentose Pvt. Ltd. | DRP-4827-02 | Oct 16, 2029 | |
FinophexFinasteride | 1mg Film-Coated TabletAlu-Alu Blister Pack X 10’S (Box of 30's) | Rx | Base Medico Private LimitedIndia | AMB HK Enterprises, Inc. | DRP-18536 | Jul 27, 2031 | |
FinophexFinasteride | 5mg Film-Coated TabletAlu-Alu Blister Pack X 10’S (Box of 30's) | Rx | Base Medico Private LimitedIndia | AMB HK Enterprises, Inc. | DRP-18537 | Jul 27, 2031 | |
FinprosFinasteride | 5 mg Film Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 3 blister packs x 10's) | Rx | Sapphire Lifesciences Pvt. Ltd.India | Ambitech Biopharmaceuticals Inc.Importer: Nelpa Lifesciences, Inc. | DRP-12349-01 | Jul 22, 2027 | |
Finstal 1Finasteride | 1 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 30's) | Rx | Stallion Laboratories Pvt. Ltd.India | Ambica International Corporation | DRP-4688 | Sep 4, 2028 | |
Finstal-5Finasteride | 5 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's Box of 30's | Rx | Stallion Laboratories Pvt. Ltd.India | Genace Pharma DistributorImporter: Ambica International Corporation | DRP-4265 | Feb 26, 2028 | |
FisterideFinasteride | 5 mg TabletAlu-Alu Blister pack x 10's (Box of 50's) | Rx | Atoz PharmaceuticalsIndia | TGP Pharma Inc.Importer: Synergen Pharma Inc.Trader: Synergen Asia Pte. Ltd. | DRP-2549-01 | Aug 28, 2029 | |
GoRocky F1Finasteride | 1 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30’s) | Rx | Sydler Remedies Pvt. LimitedIndia | GoRocky Medical Inc.Importer: Ambica International Corporation | DRP-5349-03 | Jun 18, 2029 | |
GosteridFinasteride | 5 mg Film-Coated TabletAlu/PVC Blister Pack x 10's )Box of 100's) | Rx | UNICURE REMEDIES PVT. LTD.India | POMONA PHARMACEUTICAL DISTRIBUTIONImporter: NEXT CHEMICAL ENTERPRISES | DRP-4731-02 | Apr 8, 2028 | |
HaiRestoreFinasteride | 1 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30’s) | Rx | Sydler Remedies Pvt. LimitedIndia | Ambicare Pharmaceuticals Inc.Importer: Ambica International Corporation | DRP-5349-02 | Jun 18, 2029 | |
NoneFinasteride | 5 mg Film-Coated TabletAlu-Alu blister pack x 10's (Box of 30's) | Rx | Magbro Healthcare Pvt. Ltd.India | Reta DrugImporter: Teramedix Pharma Trading Inc. | DRP-15639-01 | Aug 13, 2029 | |
NoneFinasteride | 5 mg Film-Coated TabletAlu-Clear PVC Blister Pack of 10's Box of 30's and 100's | Rx | Sydler Remedies Pvt. LimitedIndia | Actimed, Inc.Importer: I.E. Medica, Inc. | DRP-3409-02 | Nov 29, 2029 | |
NoneFinasteride | 5 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's Box of 30's | Rx | Stallion Laboratories Pvt. Ltd.India | Ambicare Pharmaceuticals Inc.Importer: Ambica International Corporation | DRP-4265-01 | Feb 26, 2028 | |
NoneFinasteride | 5 mg Film-Coated TabletAlu/ PVC Blister Pack x 10’s (Box of 100’s) | Rx | West Coast Pharmaceutical Works Ltd.India | Reta DrugImporter: Ambica International CorporationTrader: Swati Spentose Pvt. Ltd. | DRP-4827-01 | Oct 16, 2029 | |
Pelosta-5Finasteride | 5 mg Film -Coated TabletAlu-Clear PVC Blister Pack x 10's (Box of 30's and 100's) | Rx | Sydler Remedies Pvt. Ltd.India | I.E. Medica, Inc. | DRP-3409 | Nov 29, 2029 | |
PronasFinasteride | 5 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 20's (Box of 20's and 100's) | Rx | Drugmaker's Laboratories, Inc.Philippines | — | DRP-5542 | Aug 30, 2030 | |
PropeciaFinasteride | 1 mg TabletAlu/ Alu Blister Pack x 7's Box of 28 's | Rx | AIAC INTERNATIONAL PHARMA, LLC.USA | Importer: ORGANON (PHILIPPINES) INCORPORATED | DR-XY25359 | May 21, 2028 | |
Pros-medFinasteride | 5 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Magbro Healthcare Pvt. Ltd.India | Teramedix Pharma Trading Inc. | DRP-15639 | Aug 13, 2029 | |
ProscarFinasteride | 5 mg TabletBlister Pack x 15's (Box of 30's); Blister Pack x 5's (Box of 30's) | Rx | Aiac International Pharma, Llc.USA | Importer: Organon (Philippines) Incorporated | DR-XY16541 | Apr 25, 2031 | |
ProsrideFinasteride | 5 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 100's) | Rx | UNICURE REMEDIES PVT. LTD.India | TRIPLE TACT IMPORT & EXPORT CORP.Importer: NEXT CHEMICAL ENTERPRISES | DRP-4731-01 | Apr 8, 2028 | |
Prosta-OneFinasteride | 5 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30’s) | Rx | Sydler Remedies Pvt. Ltd.India | One Pharma Marketing Inc.Importer: Ambica International Corporation | DRP-4703-02 | Sep 9, 2028 | |
Prosta-OneFinasteride | 5 mg TabletAlu-Alu Blister Pack x 10's Box of 50's | Rx | Atoz PharmaceuticalsIndia | One Pharma Marketing Inc.Importer: Synergen Pharma Inc.Trader: Synergen Asia Pte., Ltd. | DRP-2549-02 | Aug 28, 2029 | |
ProstakonFinasteride | 5 mg Film-Coated TabletAlu/Alu blister pack x 10's (Box of 30's) | Rx | Magbro Healthcare Pvt. Ltd.India | Pharmakon Biotec Inc. | DRP-13926 | May 18, 2028 | |
ProstrideFinasteride | 5 mg Film Coated TabletAlu/PVC/PVDC Blister Pack x 10's (Box of 30's) | Rx | Alkem Laboratories LimitedIndia | Alkem Laboratories Corporation | DR-XY48058 | May 27, 2027 | |
ProstwinFinasteride | 5 mg Film-Coated TabletAlu-Clear PVC Blister Pack x 10's (Box of 100's) | Rx | Sydler Remedies Pvt. Ltd.India | Vitalife Pharma & Medical Supply Inc.Importer: I.E. Medica, Inc. | DRP-3409-03 | Nov 29, 2029 | |
Saphteride-5Finasteride | 5 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 3 blister packs | Rx | Sai Parenterals Ltd.India | Nelpa Lifesciences Inc. | DRP-12349 | May 26, 2030 | |
StercarFinasteride | 5 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Mega Lifesciences Public Company LimitedThailand | Mega Lifesciences Limited Inc. | DR-XY49161 | Aug 6, 2029 | |
SterciaFinasteride | 1 mg Film-Coated tabletAlu/Alu Blister Pack x 7's (Box of 28's) | Rx | Mega Lifesciences Public Company LimitedThailand | Metro Drug, Inc.Importer: Mega Lifesciences Limited Inc. | DR-XY45336 | Apr 26, 2031 | |
StericaFinasteride | 5 mg Film-Coated TabletAlu/PVC Blister Pack x 10 's (Box of 100's) | Rx | UNICURE REMEDIES PVT. LTD.India | GREENCORE PHARMA INC.Importer: NEXT CHEMICAL ENTERPRISES | DRP-4731-03 | Apr 8, 2028 | |
UlfinasteFinasteride | 5 mg TabletAlu-Alu blister pack x 10's (Box of 50's) | Rx | Atoz PharmaceuticalsIndia | Importer: Synergen Pharma Inc.Trader: Synergen Asia Pte. Ltd. | DRP-2549 | Aug 28, 2029 | |
UnbrandedFinasteride | 5 mg Film-Coated Tablet | Rx | — | — | DR-XY40487 | Dec 28, 2026 | |
Vexfin 5Finasteride | 5 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30’s) | Rx | Akums Drugs & Pharmaceuticals Ltd.India | VE PHARMA INC.Trader: Vexxa Lifesciences Pvt. Ltd | DR-XY43944 | Dec 3, 2029 | |
XpeciaFinasteride | 5 mg TabletAlu/Clear PVC Blister Pack x 10's (Box of 30's) | Rx | Globela Pharma Private Limited.India | Amb Hk Enterprises Inc.Importer: AMB HK Enterprises Inc. | DRP-16110 | Oct 30, 2029 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
United States (label)
Dosage forms and strengths (US label) US FDA label
3 DOSAGE FORMS AND STRENGTHS 5-mg blue, modified apple-shaped, film-coated tablets, with the code MSD 72 on one side and PROSCAR on the other. 5-mg film-coated tablets (3).
Warnings/Precautions
PROSCAR reduces serum prostate specific antigen (PSA) levels by approximately 50%. However, any confirmed increase in PSA while on PROSCAR may signal the presence of prostate cancer and should be evaluated, even if those values are still within the normal range for men not taking a 5α-reductase inhibitor (5.1). PROSCAR may increase the risk of high-grade prostate cancer (5.2, 6.1).
Females should not handle crushed or broken PROSCAR tablets when they are pregnant or may potentially be pregnant due to potential risk to a male fetus (5.3, 8.1, 16). PROSCAR is not indicated for use in pediatric patients or females (5.4, 8.1, 8.2, 8.4, 12.3). Prior to initiating treatment with PROSCAR for BPH, consideration should be given to other urological conditions that may cause similar symptoms (5.6).
5.1 Effects on Prostate Specific Antigen (PSA) and the Use of PSA
5.1 Effects on Prostate Specific Antigen (PSA) and the Use of PSA in Prostate Cancer Detection In clinical studies, PROSCAR reduced serum PSA concentration by approximately 50% within six months of treatment. This decrease is predictable over the entire range of PSA values in patients with symptomatic BPH, although it may vary in individuals.
For interpretation of serial PSAs in men taking PROSCAR, a new PSA baseline should be established at least six months after starting treatment and PSA monitored periodically thereafter. Any confirmed increase from the lowest PSA value while on PROSCAR may signal the presence of prostate cancer and should be evaluated, even if PSA levels are still within the normal range for men not taking a 5α-reductase inhibitor.
Non-compliance with PROSCAR therapy may also affect PSA test results. To interpret an isolated PSA value in patients treated with PROSCAR for six months or more, PSA values should be doubled for comparison with normal ranges in untreated men. These adjustments preserve the utility of PSA to detect prostate cancer in men treated with PROSCAR.
PROSCAR may also cause decreases in serum PSA in the presence of prostate cancer. The ratio of free to total PSA (percent free PSA) remains constant even under the influence of PROSCAR. If clinicians elect to use percent free PSA as an aid in the detection of prostate cancer in men undergoing finasteride therapy, no adjustment to its value appears necessary.
5.2 Increased Risk of High-Grade Prostate Cancer
5.2 Increased Risk of High-Grade Prostate Cancer Men aged 55 and over with a normal digital rectal examination and PSA ≤3.0 ng/mL at baseline taking finasteride 5 mg/day in the 7-year Prostate Cancer Prevention Trial (PCPT) had an increased risk of Gleason score 8-10 prostate cancer (finasteride 1.8% vs placebo 1.1%). [See Indications and Usage (1.3) and Adverse Reactions (6.1).] Similar results were observed in a 4-year placebo-controlled clinical trial with another 5α-reductase inhibitor (dutasteride, AVODART) (1% dutasteride vs 0.5% placebo). 5α-reductase inhibitors may increase the risk of development of high-grade prostate cancer. Whether the effect of 5α-reductase inhibitors to reduce prostate volume, or study-related factors, impacted the results of these studies has not been established.
5.3 Exposure of Females
5.3 Exposure of Females — Risk to Male Fetus PROSCAR is contraindicated in pregnant females and in females who may potentially be pregnant and not indicated for use in females. Based on animal studies and the mechanism of action, PROSCAR may cause abnormal development of external genitalia in a male fetus if administered to a pregnant female.
Females who are pregnant or may potentially be pregnant should not handle crushed or broken PROSCAR tablets. PROSCAR tablets are coated and will prevent contact with the active ingredient during normal handling, provided that the tablets have not been broken or crushed. If a pregnant female comes in contact with crushed or broken PROSCAR tablets, the contact area should be washed immediately with soap and water. [See Contraindications (4), Use in Specific Populations (8.1), Clinical Pharmacology (12.1 and 12.3), and How Supplied/Storage and Handling (16).]
5.4 Pediatric Patients and Females
5.4 Pediatric Patients and Females PROSCAR is not indicated for use in pediatric patients [see Use in Specific Populations (8.4) and Clinical Pharmacology (12.3)] or females [see also Warnings and Precautions (5.3), Use in Specific Populations (8.1), Clinical Pharmacology (12.3), and How Supplied/Storage and Handling (16)].
5.5 Effect on Semen Characteristics Treatment
5.5 Effect on Semen Characteristics Treatment with PROSCAR for 24 weeks to evaluate semen parameters in healthy male volunteers revealed no clinically meaningful effects on sperm concentration, mobility, morphology, or pH. A 0.6 mL (22.1%) median decrease in ejaculate volume with a concomitant reduction in total sperm per ejaculate was observed.
These parameters remained within the normal range and were reversible upon discontinuation of therapy with an average time to return to baseline of 84 weeks.
5.6 Consideration of Other Urological Conditions
5.6 Consideration of Other Urological Conditions Prior to initiating treatment with PROSCAR, consideration should be given to other urological conditions that may cause similar symptoms. In addition, prostate cancer and BPH may coexist. Patients with large residual urinary volume and/or severely diminished urinary flow should be carefully monitored for obstructive uropathy.
These patients may not be candidates for finasteride therapy.
Drug interactions
7.1 Cytochrome P450-Linked Drug Metabolizing Enzyme System
7.1 Cytochrome P450-Linked Drug Metabolizing Enzyme System No drug interactions of clinical importance have been identified. Finasteride does not appear to affect the cytochrome P450-linked drug metabolizing enzyme system. Compounds that have been tested in man have included antipyrine, digoxin, propranolol, theophylline, and warfarin and no clinically meaningful interactions were found.
7.2 Other Concomitant Therapy
7.2 Other Concomitant Therapy Although specific interaction studies were not performed, PROSCAR was concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, α-blockers, angiotensin-converting enzyme (ACE) inhibitors, analgesics, anti-convulsants, beta-adrenergic blocking agents, diuretics, calcium channel blockers, cardiac nitrates, HMG-CoA reductase inhibitors, nonsteroidal anti-inflammatory drugs (NSAIDs), benzodiazepines, H 2 antagonists and quinolone anti-infectives without evidence of clinically significant adverse interactions.
Adverse reactions
The drug-related adverse reactions, reported in ≥1% in patients treated with PROSCAR and greater than in patients treated with placebo over a 4-year study are: impotence, decreased libido, decreased volume of ejaculate, breast enlargement, breast tenderness and rash (6.1). To report SUSPECTED ADVERSE REACTIONS, contact Organon LLC, a subsidiary of Organon & Co., at 1-844-674-3200 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
6.1 Clinical Trials Experience
6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. 4-Year Placebo-Controlled Study (PLESS) In PLESS, 1524 patients treated with PROSCAR and 1516 patients treated with placebo were evaluated for safety over a period of 4 years. The most frequently reported adverse reactions were related to sexual function. 3.7% (57 patients) treated with PROSCAR and 2.1% (32 patients) treated with placebo discontinued therapy as a result of adverse reactions related to sexual function, which are the most frequently reported adverse reactions.
Table 1 presents the only clinical adverse reactions considered possibly, probably or definitely drug related by the investigator, for which the incidence on PROSCAR was ≥1% and greater than placebo over the 4 years of the study. In years 2-4 of the study, there was no significant difference between treatment groups in the incidences of impotence, decreased libido and ejaculation disorder.
Table 1: Drug-Related Adverse Experiences Year 1 (%) Years 2, 3 and 4 Combined Years 2-4 (%) Finasteride Placebo Finasteride Placebo N = 1524 and 1516, finasteride vs placebo, respectively Impotence 8.1 3.7 5.1 5.1 Decreased Libido 6.4 3.4 2.6 2.6 Decreased Volume of Ejaculate 3.7 0.8 1.5 0.5 Ejaculation Disorder 0.8 0.1 0.2 0.1 Breast Enlargement 0.5 0.1 1.8 1.1 Breast Tenderness 0.4 0.1 0.7 0.3 Rash 0.5 0.2 0.5 0.1 Phase III Studies and 5-Year Open Extensions The adverse experience profile in the 1-year, placebo-controlled, Phase III studies, the 5-year open extensions, and PLESS were similar. Medical Therapy of Prostatic Symptoms (MTOPS) Study In the MTOPS study, 3047 men with symptomatic BPH were randomized to receive PROSCAR 5 mg/day (n=768), doxazosin 4 or 8 mg/day (n=756), the combination of PROSCAR 5 mg/day and doxazosin 4 or 8 mg/day (n=786), or placebo (n=737) for 4 to 6 years. [See Clinical Studies (14.2).] The incidence rates of drug-related adverse experiences reported by ≥2% of patients in any treatment group in the MTOPS Study are listed in Table 2.
The individual adverse effects which occurred more frequently in the combination group compared to either drug alone were: asthenia, postural hypotension, peripheral edema, dizziness, decreased libido, rhinitis, abnormal ejaculation, impotence and abnormal sexual function (see Table 2). Of these, the incidence of abnormal ejaculation in patients receiving combination therapy was comparable to the sum of the incidences of this adverse experience reported for the two monotherapies.
Combination therapy with finasteride and doxazosin was associated with no new clinical adverse experience. Four patients in MTOPS reported the adverse experience breast cancer. Three of these patients were on finasteride only and one was on combination therapy. [See Long-Term Data.] The MTOPS Study was not specifically designed to make statistical comparisons between groups for reported adverse experiences.
In addition, direct comparisons of safety data between the MTOPS study and previous studies of the single agents may not be appropriate based upon differences in patient population, dosage or dose regimen, and other procedural and study design elements. Table 2: Incidence ≥2% in One or More Treatment Groups Drug-Related Clinical Adverse Experiences in MTOPS Adverse Experience Placebo (N=737) (%) Doxazosin 4 mg or 8 mg Doxazosin dose was achieved by weekly titration (1 to 2 to 4 to 8 mg).
The final tolerated dose (4 mg or 8 mg) was administered at end-Week 4. Only those patients tolerating at least 4 mg were kept on doxazosin. The majority of patients received the 8-mg dose over the duration of the study. (N=756) (%) Finasteride (N=768) (%) Combination (N=786) (%) Body as a whole Asthenia 7.1 15.7 5.3 16.8 Headache 2.3 4.1 2.0 2.3 Cardiovascular Hypotension 0.7 3.4 1.2 1.5 Postural Hypotension 8.0 16.7 9.1 17.8 Metabolic and Nutritional Peripheral Edema 0.9 2.6 1.3 3.3 Nervous Dizziness 8.1 17.7 7.4 23.2 Libido Decreased 5.7 7.0 10.0 11.6 Somnolence 1.5 3.7 1.7 3.1 Respiratory Dyspnea 0.7 2.1 0.7 1.9 Rhinitis 0.5 1.3 1.0 2.4 Urogenital Abnormal Ejaculation 2.3 4.5 7.2 14.1 Gynecomastia 0.7 1.1 2.2 1.5 Impotence 12.2 14.4 18.5 22.6 Sexual Function Abnormal 0.9 2.0 2.5 3.1 Long-Term Data High-Grade Prostate Cancer The PCPT trial was a 7-year randomized, double-blind, placebo-controlled trial that enrolled 18,882 men ≥55 years of age with a normal digital rectal examination and a PSA ≤3.0 ng/mL.
Men received either PROSCAR (finasteride 5 mg) or placebo daily. Patients were evaluated annually with PSA and digital rectal exams. Biopsies were performed for elevated PSA, an abnormal digital rectal exam, or the end of study. The incidence of Gleason score 8-10 prostate cancer was higher in men treated with finasteride (1.8%) than in those treated with placebo (1.1%) [see Indications and Usage (1.3) and Warnings and Precautions (5.2)].
In a 4-year placebo-controlled clinical trial with another 5α-reductase inhibitor (dutasteride, AVODART), similar results for Gleason score 8-10 prostate cancer were observed (1% dutasteride vs 0.5% placebo). No clinical benefit has been demonstrated in patients with prostate cancer treated with PROSCAR. Breast Cancer During the 4- to 6-year placebo- and comparator-controlled MTOPS study that enrolled 3047 men, there were 4 cases of breast cancer in men treated with finasteride but no cases in men not treated with finasteride.
During the 4-year, placebo-controlled PLESS study that enrolled 3040 men, there were 2 cases of breast cancer in placebo-treated men but no cases in men treated with finasteride. During the 7-year placebo-controlled Prostate Cancer Prevention Trial (PCPT) that enrolled 18,882 men, there was 1 case of breast cancer in men treated with finasteride, and 1 case of breast cancer in men treated with placebo.
The relationship between long-term use of finasteride and male breast neoplasia is currently unknown. Sexual Function There is no evidence of increased sexual adverse experiences with increased duration of treatment with PROSCAR. New reports of drug-related sexual adverse experiences decreased with duration of therapy.
6.2 Postmarketing Experience
6.2 Postmarketing Experience The following additional adverse events have been reported in postmarketing experience with PROSCAR. Because these events are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure: - hypersensitivity reactions, such as pruritus, urticaria, and angioedema (including swelling of the lips, tongue, throat, and face) - testicular pain - hematospermia - sexual dysfunction that continued after discontinuation of treatment, including erectile dysfunction, decreased libido and ejaculation disorders (e.g. reduced ejaculate volume).
These events were reported rarely in men taking PROSCAR for the treatment of BPH. Most men were older and were taking concomitant medications and/or had co-morbid conditions. The independent role of PROSCAR in these events is unknown. - male infertility and/or poor seminal quality were reported rarely in men taking PROSCAR for the treatment of BPH.
Normalization or improvement of poor seminal quality has been reported after discontinuation of finasteride. The independent role of PROSCAR in these events is unknown. - depression - suicidal ideation - male breast cancer. The following additional adverse event related to sexual dysfunction that continued after discontinuation of treatment has been reported in postmarketing experience with finasteride at lower doses used to treat male pattern baldness.
Because the event is reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate its frequency or establish a causal relationship to drug exposure: - orgasm disorders
Adverse reaction frequency tables (US label) US FDA label
| Year 1 (%) | Years 2, 3 and 4Combined Years 2-4 (%) | |||
|---|---|---|---|---|
| Finasteride | Placebo | Finasteride | Placebo | |
| N = 1524 and 1516, finasteride vs placebo, respectively | ||||
| Impotence | 8.1 | 3.7 | 5.1 | 5.1 |
| Decreased Libido | 6.4 | 3.4 | 2.6 | 2.6 |
| Decreased Volume of Ejaculate | 3.7 | 0.8 | 1.5 | 0.5 |
| Ejaculation Disorder | 0.8 | 0.1 | 0.2 | 0.1 |
| Breast Enlargement | 0.5 | 0.1 | 1.8 | 1.1 |
| Breast Tenderness | 0.4 | 0.1 | 0.7 | 0.3 |
| Rash | 0.5 | 0.2 | 0.5 | 0.1 |
| Adverse Experience | Placebo (N=737) (%) | Doxazosin 4 mg or 8 mgDoxazosin dose was achieved by weekly titration (1 to 2 to 4 to 8 mg). The final tolerated dose (4 mg or 8 mg) was administered at end-Week 4. Only those patients tolerating at least 4 mg were kept on doxazosin. The majority of patients received the 8-mg dose over the duration of the study. (N=756) (%) | Finasteride (N=768) (%) | Combination (N=786) (%) |
|---|---|---|---|---|
| Body as a whole | ||||
| Asthenia | 7.1 | 15.7 | 5.3 | 16.8 |
| Headache | 2.3 | 4.1 | 2.0 | 2.3 |
| Cardiovascular | ||||
| Hypotension | 0.7 | 3.4 | 1.2 | 1.5 |
| Postural Hypotension | 8.0 | 16.7 | 9.1 | 17.8 |
| Metabolic and Nutritional | ||||
| Peripheral Edema | 0.9 | 2.6 | 1.3 | 3.3 |
| Nervous | ||||
| Dizziness | 8.1 | 17.7 | 7.4 | 23.2 |
| Libido Decreased | 5.7 | 7.0 | 10.0 | 11.6 |
| Somnolence | 1.5 | 3.7 | 1.7 | 3.1 |
| Respiratory | ||||
| Dyspnea | 0.7 | 2.1 | 0.7 | 1.9 |
| Rhinitis | 0.5 | 1.3 | 1.0 | 2.4 |
| Urogenital | ||||
| Abnormal Ejaculation | 2.3 | 4.5 | 7.2 | 14.1 |
| Gynecomastia | 0.7 | 1.1 | 2.2 | 1.5 |
| Impotence | 12.2 | 14.4 | 18.5 | 22.6 |
| Sexual Function Abnormal | 0.9 | 2.0 | 2.5 | 3.1 |
Pregnancy considerations
Pregnancy (US label) US FDA label
8.1 Pregnancy Risk Summary PROSCAR is contraindicated in pregnant females and not indicated for use in females. Based on animal studies and the mechanism of action, PROSCAR may cause abnormal development of external genitalia in a male fetus if administered to a pregnant female [see Warnings and Precautions (5.3) and Clinical Pharmacology (12.1)].
In an embryo-fetal development study in rats, there was a dose-dependent increase in hypospadias that occurred in 3.6 to 100% of male offspring of pregnant rats administered oral finasteride during the period of major organogenesis at doses approximately 0.1 to 86 times the maximum recommended human dose (MRHD) of 5 mg/day (based on AUC at animal doses of 0.1 to 100 mg/kg/day). Decreased prostatic and seminal vesicular weights, delayed preputial separation and transient nipple development were also observed in male offspring at oral maternal doses approximately 0.03 times the MRHD (based on AUC at animal dose of 0.03 mg/kg/day), along with decreased anogenital distance in male offspring at oral maternal doses approximately 0.003 times the MRHD (based on AUC at animal dose of 0.003 mg/kg/day).
PROSCAR is a Type II 5α-reductase inhibitor that prevents conversion of testosterone to 5α-dihydrotestosterone (DHT), a hormone necessary for normal development of male genitalia. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the male fetus.
Abnormal male genital development is an expected consequence when conversion of testosterone to 5α-dihydrotestosterone (DHT) is inhibited by 5α-reductase inhibitors. These outcomes are similar to those reported in male infants with genetic 5α-reductase deficiency. Females could be exposed to finasteride through contact with crushed or broken PROSCAR tablets or semen from a male partner taking PROSCAR.
With regard to finasteride exposure through the skin, PROSCAR tablets are coated and will prevent skin contact with finasteride during normal handling if the tablets have not been crushed or broken. Females who are pregnant or may potentially be pregnant should not handle crushed or broken PROSCAR tablets because of possible exposure of a male fetus.
With regard to potential finasteride exposure through semen, three studies have been conducted that measured finasteride concentrations in semen in men receiving PROSCAR 5 mg/day. In these studies the highest amount of finasteride in semen was estimated to be 50- to 100-fold less than the dose of finasteride (5 μg) that had no effect on circulating DHT levels in men [see Data and Clinical Pharmacology (12.3)].
Data Human Data In 2 studies of healthy subjects (n=69) receiving PROSCAR 5 mg/day for 6-24 weeks, finasteride concentrations in semen ranged from undetectable (<0.1 ng/mL) to 10.54 ng/mL. In an earlier study using a less sensitive assay, finasteride concentrations in semen of 16 subjects receiving PROSCAR 5 mg/day ranged from undetectable (<1.0 ng/mL) to 21 ng/mL.
Using the highest semen level measured and assuming 100% absorption would be up to 105 ng per day, which is 50- to 100-fold less than the dose of finasteride (5 μg) that had no effect on circulating DHT levels in men [see Clinical Pharmacology (12.3)]. Animal Data In an embryo-fetal development study, pregnant rats received finasteride during the period of major organogenesis (gestation days 6 to 17).
At maternal doses of oral finasteride approximately 0.1 to 86 times the maximum recommended human dose (MRHD) of 5 mg/day (based on AUC at animal doses of 0.1 to 100 mg/kg/day) there was a dose-dependent increase in hypospadias that occurred in 3.6 to 100% of male offspring. Exposure multiples were estimated using data from nonpregnant rats.
Days 16 to 17 of gestation is a critical period in male fetal rats for differentiation of the external genitalia. At oral maternal doses approximately 0.03 times the MRHD (based on AUC at animal dose of 0.03 mg/kg/day), male offspring had decreased prostatic and seminal vesicular weights, delayed preputial separation and transient nipple development.
Decreased anogenital distance occurred in male offspring of pregnant rats that received approximately 0.003 times the MRHD (based on AUC at animal dose of 0.003 mg/kg/day). No abnormalities were observed in female offspring at any maternal dose of finasteride. No developmental abnormalities were observed in the offspring of untreated females mated with finasteride treated male rats that received approximately 61 times the MRHD (based on AUC at animal dose of 80 mg/kg/day).
Slightly decreased fertility was observed in male offspring after administration of about 3 times the MRHD (based on AUC at animal dose of 3 mg/kg/day) to female rats during late gestation and lactation. No effects on fertility were seen in female offspring under these conditions. No evidence of male external genital malformations or other abnormalities were observed in rabbit fetuses exposed to finasteride during the period of major organogenesis (gestation days 6-18) at maternal oral doses up to 100 mg/kg/day, (finasteride exposure levels were not measured in rabbits).
However, this study may not have included the critical period for finasteride effects on development of male external genitalia in the rabbit. The fetal effects of maternal finasteride exposure during the period of embryonic and fetal development were evaluated in the rhesus monkey (gestation days 20-100), in a species and development period more predictive of specific effects in humans than the studies in rats and rabbits.
Intravenous administration of finasteride to pregnant monkeys at doses as high as 800 ng/day (estimated maximal blood concentration of 1.86 ng/mL or about 143 times the highest estimated exposure of pregnant females to finasteride from semen of men taking 5 mg/day) resulted in no abnormalities in male fetuses. In confirmation of the relevance of the rhesus model for human fetal development, oral administration of a dose of finasteride (2 mg/kg/day or approximately 18,000 times the highest estimated blood levels of finasteride from semen of men taking 5 mg/day) to pregnant monkeys resulted in external genital abnormalities in male fetuses.
No other abnormalities were observed in male fetuses and no finasteride-related abnormalities were observed in female fetuses at any dose.
Mechanism of action
12.1 Mechanism of Action The development and enlargement of the prostate gland is dependent on the potent androgen, 5α-dihydrotestosterone (DHT). Type II 5α-reductase metabolizes testosterone to DHT in the prostate gland, liver and skin. DHT induces androgenic effects by binding to androgen receptors in the cell nuclei of these organs.
Finasteride is a competitive and specific inhibitor of Type II 5α-reductase with which it slowly forms a stable enzyme complex. Turnover from this complex is extremely slow (t ½ ~ 30 days). This has been demonstrated both in vivo and in vitro. Finasteride has no affinity for the androgen receptor. In man, the 5α-reduced steroid metabolites in blood and urine are decreased after administration of finasteride.
US FDA labelPharmacodynamics
Pharmacodynamics (US label) US FDA label
12.2 Pharmacodynamics In man, a single 5-mg oral dose of PROSCAR produces a rapid reduction in serum DHT concentration, with the maximum effect observed 8 hours after the first dose. The suppression of DHT is maintained throughout the 24-hour dosing interval and with continued treatment. Daily dosing of PROSCAR at 5 mg/day for up to 4 years has been shown to reduce the serum DHT concentration by approximately 70%.
The median circulating level of testosterone increased by approximately 10-20% but remained within the physiologic range. In a separate study in healthy men treated with finasteride 1 mg per day (n=82) or placebo (n=69), mean circulating levels of testosterone and estradiol were increased by approximately 15% as compared to baseline, but these remained within the physiologic range.
In patients receiving PROSCAR 5 mg/day, increases of about 10% were observed in luteinizing hormone (LH) and follicle-stimulating hormone (FSH), but levels remained within the normal range. In healthy volunteers, treatment with PROSCAR did not alter the response of LH and FSH to gonadotropin-releasing hormone indicating that the hypothalamic-pituitary-testicular axis was not affected.
In patients with BPH, PROSCAR has no effect on circulating levels of cortisol, prolactin, thyroid-stimulating hormone, or thyroxine. No clinically meaningful effect was observed on the plasma lipid profile (i.e., total cholesterol, low density lipoproteins, high density lipoproteins and triglycerides) or bone mineral density.
Adult males with genetically inherited Type II 5α-reductase deficiency also have decreased levels of DHT. Except for the associated urogenital defects present at birth, no other clinical abnormalities related to Type II 5α-reductase deficiency have been observed in these individuals. These individuals have a small prostate gland throughout life and do not develop BPH.
In patients with BPH treated with finasteride (1-100 mg/day) for 7-10 days prior to prostatectomy, an approximate 80% lower DHT content was measured in prostatic tissue removed at surgery, compared to placebo; testosterone tissue concentration was increased up to 10 times over pretreatment levels, relative to placebo. Intraprostatic content of PSA was also decreased.
In healthy male volunteers treated with PROSCAR for 14 days, discontinuation of therapy resulted in a return of DHT levels to pretreatment levels in approximately 2 weeks. In patients treated for three months, prostate volume, which declined by approximately 20%, returned to close to baseline value after approximately three months of discontinuation of therapy.
Pharmacokinetics
Excretion In healthy young subjects (n=15), mean plasma clearance of finasteride was 165 mL/min (range, 70-279 mL/min) and mean elimination half-life in plasma was 6 hours (range, 3-16 hours).
Following an oral dose of 14 C-finasteride in man (n=6), a mean of 39% (range, 32-46%) of the dose was excreted in the urine in the form of metabolites; 57% (range, 51-64%) was excreted in the feces.
The mean terminal half-life of finasteride in subjects ≥70 years of age was approximately 8 hours (range, 6-15 hours; n=12), compared with 6 hours (range, 4-12 hours; n=12) in subjects 45-60 years of age.
Table 3: Mean (SD) Pharmacokinetic Parameters in Healthy Young Subjects (n=15) Mean (± SD) Bioavailability 63% (34-108%) Range Clearance (mL/min) 165 (55) Volume of Distribution (L) 76 (14) Half-Life (hours) 6.2 (2.1) Pediatric Finasteride pharmacokinetics have not been investigated in patients <18 years of age.
[See Clinical Pharmacology (12.3) and Use in Specific Populations (8.5) .] Table 4: Mean (SD) Noncompartmental Pharmacokinetic Parameters After Multiple Doses of 5 mg/day in Older Men Mean (± SD) 45-60 years old (n=12) ≥70 years old (n=12) AUC (ng•hr/mL) 389 (98) 463 (186) Peak Concentration (ng/mL) 46.2 (8.7) 48.4 (14.7) Time to Peak (hours) 1.8 (0.7) 1.8 (0.6) Half-Life (hours) First-dose values; all other parameters are last-dose values 6.0 (1.5) 8.2 (2.5) Race The effect of race on finasteride pharmacokinetics has not been studied.
Pharmacokinetics (US label) US FDA label
12.3 Pharmacokinetics Absorption In a study of 15 healthy young subjects, the mean bioavailability of finasteride 5-mg tablets was 63% (range 34-108%), based on the ratio of area under the curve (AUC) relative to an intravenous (IV) reference dose. Maximum finasteride plasma concentration averaged 37 ng/mL (range, 27-49 ng/mL) and was reached 1-2 hours postdose.
Bioavailability of finasteride was not affected by food. Distribution Mean steady-state volume of distribution was 76 liters (range, 44-96 liters). Approximately 90% of circulating finasteride is bound to plasma proteins. There is a slow accumulation phase for finasteride after multiple dosing. After dosing with 5 mg/day of finasteride for 17 days, plasma concentrations of finasteride were 47 and 54% higher than after the first dose in men 45-60 years old (n=12) and ≥70 years old (n=12), respectively.
Mean trough concentrations after 17 days of dosing were 6.2 ng/mL (range, 2.4-9.8 ng/mL) and 8.1 ng/mL (range, 1.8-19.7 ng/mL), respectively, in the two age groups. Although steady state was not reached in this study, mean trough plasma concentration in another study in patients with BPH (mean age, 65 years) receiving 5 mg/day was 9.4 ng/mL (range, 7.1-13.3 ng/mL; n=22) after over a year of dosing.
Finasteride has been shown to cross the blood brain barrier but does not appear to distribute preferentially to the CSF. In 2 studies of healthy subjects (n=69) receiving PROSCAR 5 mg/day for 6-24 weeks, finasteride concentrations in semen ranged from undetectable (<0.1 ng/mL) to 10.54 ng/mL. In an earlier study using a less sensitive assay, finasteride concentrations in the semen of 16 subjects receiving PROSCAR 5 mg/day ranged from undetectable (<1.0 ng/mL) to 21 ng/mL.
Thus, based on a 5-mL ejaculate volume, the amount of finasteride in semen was estimated to be 50- to 100-fold less than the dose of finasteride (5 μg) that had no effect on circulating DHT levels in men [see also Use in Specific Populations (8.1)]. Metabolism Finasteride is extensively metabolized in the liver, primarily via the cytochrome P450 3A4 enzyme subfamily.
Two metabolites, the t-butyl side chain monohydroxylated and monocarboxylic acid metabolites, have been identified that possess no more than 20% of the 5α-reductase inhibitory activity of finasteride. Excretion In healthy young subjects (n=15), mean plasma clearance of finasteride was 165 mL/min (range, 70-279 mL/min) and mean elimination half-life in plasma was 6 hours (range, 3-16 hours).
Following an oral dose of 14 C-finasteride in man (n=6), a mean of 39% (range, 32-46%) of the dose was excreted in the urine in the form of metabolites; 57% (range, 51-64%) was excreted in the feces. The mean terminal half-life of finasteride in subjects ≥70 years of age was approximately 8 hours (range, 6-15 hours; n=12), compared with 6 hours (range, 4-12 hours; n=12) in subjects 45-60 years of age.
As a result, mean AUC (0-24 hr) after 17 days of dosing was 15% higher in subjects ≥70 years of age than in subjects 45-60 years of age (p=0.02). Table 3: Mean (SD) Pharmacokinetic Parameters in Healthy Young Subjects (n=15) Mean (± SD) Bioavailability 63% (34-108%) Range Clearance (mL/min) 165 (55) Volume of Distribution (L) 76 (14) Half-Life (hours) 6.2 (2.1) Pediatric Finasteride pharmacokinetics have not been investigated in patients <18 years of age.
Finasteride is not indicated for use in pediatric patients [see Warnings and Precautions (5.4), Use in Specific Populations (8.4)]. Gender Finasteride is not indicated for use in females [see Contraindications (4), Warnings and Precautions (5.3 and 5.4), Use in Specific Populations (8.1), and How Supplied/Storage and Handling (16)].
Geriatric No dosage adjustment is necessary in the elderly. Although the elimination rate of finasteride is decreased in the elderly, these findings are of no clinical significance. [See Clinical Pharmacology (12.3) and Use in Specific Populations (8.5).] Table 4: Mean (SD) Noncompartmental Pharmacokinetic Parameters After Multiple Doses of 5 mg/day in Older Men Mean (± SD) 45-60 years old (n=12) ≥70 years old (n=12) AUC (ng•hr/mL) 389 (98) 463 (186) Peak Concentration (ng/mL) 46.2 (8.7) 48.4 (14.7) Time to Peak (hours) 1.8 (0.7) 1.8 (0.6) Half-Life (hours) First-dose values; all other parameters are last-dose values 6.0 (1.5) 8.2 (2.5) Race The effect of race on finasteride pharmacokinetics has not been studied.
Hepatic Impairment The effect of hepatic impairment on finasteride pharmacokinetics has not been studied. Caution should be exercised in the administration of PROSCAR in those patients with liver function abnormalities, as finasteride is metabolized extensively in the liver. Renal Impairment No dosage adjustment is necessary in patients with renal impairment.
In patients with chronic renal impairment, with creatinine clearances ranging from 9.0 to 55 mL/min, AUC, maximum plasma concentration, half-life, and protein binding after a single dose of 14 C-finasteride were similar to values obtained in healthy volunteers. Urinary excretion of metabolites was decreased in patients with renal impairment.
This decrease was associated with an increase in fecal excretion of metabolites. Plasma concentrations of metabolites were significantly higher in patients with renal impairment (based on a 60% increase in total radioactivity AUC). However, finasteride has been well tolerated in BPH patients with normal renal function receiving up to 80 mg/day for 12 weeks, where exposure of these patients to metabolites would presumably be much greater.
Formulary and pricing (Philippines)
Government price references
| Preparation | Price (PHP) | Unit | Type |
|---|---|---|---|
| Finasteride 5 mg Tablet | ₱5.00–₱18.00Reference ₱8.25 | per tablet | DPRI procurement range |
Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)
These are government procurement and reimbursement references, not retail prices. Sources:
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf, as of September 17, 2021
Formulary and coverage
| Philippine National Formulary | Listed as Finasteride |
| PNF listing | Oral: 5 mg tablet |
| PhilHealth GAMOT | No |
Sources:
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf, as of November 2, 2022
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- U.S. Food and Drug Administration. PROSCAR · Organon LLC [US FDA-approved label, version 9, March 18, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6f988153-fc74-4ca4-b29a-111f750c4a4b
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf
This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.
Last updated: .
